GPM #:  
Keyword:  


# GPM # proteins Description
1. GPM65240056655
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
349
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COV0006941_41_S1-F5_1_2427_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
2. GPM65240056656
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
367
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS000806_87_S2-B3_1_2477_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
3. GPM65240056657
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
366
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS000864_53_S1-G5_1_2439_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
4. GPM65240056658
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
323
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS001067_35_S1-E11_1_2421_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
5. GPM65240056659
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
358
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS001444_91_S2-B7_1_2485_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
6. GPM65240056660
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
339
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS001589_89_S2-B5_1_2479_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
7. GPM65240056661
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
335
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS001618_88_S2-B4_1_2478_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
8. GPM65240056662
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
336
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS001676_93_S2-B9_1_2487_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
9. GPM65240056663
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
346
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS002140_26_S1-E2_1_2409_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
10. GPM65240056664
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
337
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS002343_106_S2-C10_1_2500_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
11. GPM65240056665
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
366
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS003619_44_S1-F8_1_2430_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
12. GPM65240056666
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
340
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS003822_21_S1-D9_1_2404_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
13. GPM65240056667
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
348
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS004054_103_S2-C7_1_2497_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
14. GPM65240056668
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
312
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS005120_96_S2-B12_1_2490_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
15. GPM65240056669
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
329
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS005469_24_S1-D12_1_2407_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
16. GPM65240056670
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
376
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS005853_13_S1-D1_1_2396_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
17. GPM65240056671
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
424
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS006045_77_S2-A5_1_2467_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
18. GPM65240056672
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
337
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS006141_67_S1-H7_1_2457_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
19. GPM65240056673
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
361
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS006205_23_S1-D11_1_2406_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]
20. GPM65240056674
metadata 
peptide 
model 
group 
aaa 
gel
mh
go
350
  1. BRENDA cell culture: none
  2. BRENDA tissue: BTO:0000131  blood plasma
  3. CELL cell type: none
  4. GO subcellular: none
  5. email: kirk.hansen@cuanschutz.edu
  6. institution: University of Colorado
  7. name: Kirk Hansen, et al.
  8. project: COVIDomics_plasma_2020_DDA-PASEF
  9. project comment: Data from ProteomeXchange, PXD022817. File: negative_COVS006429_118_S2-D10_1_2512_calibrated.mgf. From ProteomeXchange: In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. [COVID19]

Page 1 of 7 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
Key word(s): PXD022817
Total protein ids = 44901













dblist_gpmnotes.pl, v. 2017.02.06